Skip to main content
. Author manuscript; available in PMC: 2015 Mar 9.
Published in final edited form as: Pharm Res. 2011 May 26;28(10):2477–2489. doi: 10.1007/s11095-011-0474-x

Table I.

Details of Microsphere Formulations

Formulation IDa PLGA
End-group		 BSA Excipient
[w/w]		 Solvent Vols. (W1/O)
[µL/mL]		 Sonication Temp.
[°C]		 SDF Load
[w/w]		 Size, Mean±SD
[µm]
A Acid 5% 66.5/0.7 21 0.002% 22.5±8.2
B Acid 5% 125/2.0 21 0.002% 10.1±3.2
C Ester 5% 125/2.0 21 0.002% 5.0±1.4
D Ester 0% 125/2.0 21 0.002% 4.6±1.5
E Acid 0% 66.5/0.7 21 0.002% 13.0±5.4
F Acid 0% 66.5/0.7 21 0% 14.6±6.8
G Acid 5% 66.5/0.7 0 0.002% 16.7±8.9
a

All formulations were fabricated with 100 mg of PLGA (Mw 53 kDa, 50:50 D,L-lactide:glycolide), TE-lactose as internal aqueous phase (W1), and dichloromethane as organic solvent (O).